Alnylam's gene-blocker study may help assuage safety worries

09/27/2007 | Bloomberg1

Alnylam Pharmaceutical's latest animal study may ease safety concerns over its experimental drugs derived from RNA interference, the company said. Researchers found that Alnylam's gene-blocking molecules were able to block about 80% of the genes' effects on mice without disturbing a critical cell regulation system.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC